|
Edward P. Amento, M.D. is Cofounder of
Theracos. He previously founded Connetics Corporation (formerly
Connective Therapeutics, Inc.), a public biopharmaceutical company
located in Palo Alto, California, and served as Chief Scientific
Officer. Prior to that, he directed the Rheumatology and Immunology
program at Genentech, after serving as an attending physician in the
Arthritis Unit at Massachusetts General Hospital. In 1995 Dr. Amento
also founded the Molecular Medicine Research Institute, a
not-for-profit research organization, to advance the understanding
of the molecular and cellular basis of autoimmune and connective
tissue diseases and cancer. He holds Scientific Advisory Board and
Director positions on several privately held biotechnology
companies.
Jeffrey W. Bird, M.D., Ph.D. is a Managing Director at Sutter
Hill Ventures. Prior to joining the venture community Dr. Bird was
Senior Vice President, Business Operations, at Gilead Sciences, Inc.
He was primarily responsible for several alliances with major
pharmaceutical companies and helped Gilead to acquire NeXstar in a
$550 million transaction. His commercial responsibilities included
direct sales in the US and Europe, generating $150 million in
product revenue. Dr. Bird brings to Theracos significant experience
in corporate agreements, product development and financing.
Brian Seed, Ph.D. is a Cofounder of Theracos, Professor of
Genetics at Harvard Medical School and director of the Center for
Computational and Integrative Biology at Massachusetts General
Hospital. He is known for the development of genetic methodologies
for the discovery of gene function in mammalian cells, and
contributions to understanding the function of the immune system. In
addition, he has developed technologies that are widely used today
in molecular biology. He was a cofounder of Connetics Corporation,
has cofounded several private biotechnology companies, and holds
Scientific Advisory Board and Director positions in private and
public biotechnology companies.
William M. Smith, J.D. is VP of Legal Affairs and General
Counsel at Fluidigm Corporation. Before joining Fluidigm, Mr. Smith
was a founder of the Biotechnology Practice Group at Townsend and
Townsend and Crew, LLP. At Townsend, he focused on patent
prosecution, licensing and consulting, with an emphasis on
immunology, molecular biology, pharmaceuticals, and diagnostics. Mr.
Smith’s skills in patent prosecution, licensing and strategic
portfolio planning, have been widely sought and have benefited a
diverse roster of clients including Protein Design Labs, Affymax,
Affymetrix, GenPharm, Pharming, and Geron, as well as several
multi-national healthcare companies. He has served as corporate
counsel for DNAX Research Institute of Molecular and Cellular
Biology and as co-chairman of the Biotechnology Transfer Committee
of the Licensing Executives Society.
SECRETARY TO THE BOARD
Michael Hall, J.D. of Latham & Watkins serves as Corporate
Counsel and Corporate Secretary. Mr. Hall has over twenty-five years
of experience in the life science arena. He was a partner at Wilson,
Sonsini, Goodrich & Rosati in their life sciences practice and was a
founding partner of Venture Law Group before joining Latham &
Watkins. Mr. Hall has extensive experience in corporate agreements,
corporate structure and SEC transactions.
|
